In a phase 1⁄2 study in 15 patients with hemophilia A who received a single dose of valoctocogene roxaparvovec, follow-up data to 5 years indicated that 10 out of 13 participants continued to have FVIII levels above the severe hemophilia A range (>1 IU/dL) [64]. Here, F8 is linked to hemophilia A.